NASDAQ: EPRXEupraxia Pharmaceuticals Inc Stock
$2.80-0.05 (-1.75%)
Updated Apr 26, 2024
EPRX Price
$2.80
Fair Value Price
N/A
Market Cap
N/A
52 Week Low
$2.48
52 Week High
$3.50
P/E
-2.39x
P/B
N/A
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$28.97M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
8.74
Operating Cash Flow
-$21M
Beta
-0.4
Next Earnings
Jun 6, 2024
Ex-Dividend
N/A
Next Dividend
N/A
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how EPRX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
EPRX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
EPRX is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
EPRX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more EPRX due diligence checks available for Premium users.
Be the first to know about important EPRX news, forecast changes, insider trades & much more!
EPRX News
Valuation
EPRX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.39x
Industry
14.88x
Market
41.14x
EPRX's financial health
Profit margin
Revenue
$0.0
Net Income
-$4.4M
Profit Margin
0%
EPRX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$20.3M
Liabilities
$19.4M
Debt to equity
8.74
EPRX's short-term assets ($19.80M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
EPRX's short-term assets ($19.80M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
EPRX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$878.6k
Investing
-$41.2k
Financing
-$7.3M
EPRX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
Eupraxia Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.